Table 3.
Multivariate analysis of prognostic factors of breast cancer-specific survival in different 21-gene recurrence score groups
| Variables | Low-risk
|
Intermediate-risk
|
High-risk
|
|||
|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
|
| ||||||
| Age (years) | ||||||
| <50 | 1 | 1 | 1 | |||
| ≥50 | 2.156 (1.318–3.528) | 0.002 | 1.160 (0.854–1.577) | 0.342 | 1.043 (0.723–1.505) | 0.822 |
| Race/ethnicity | ||||||
| Non-Hispanic White | 1 | 1 | 1 | |||
| Non-Hispanic Black | 1.719 (0.979–3.020) | 0.059 | 1.220 (0.782–1.904) | 0.381 | 1.247 (0.766–2.209) | 0.374 |
| Hispanic (all races) | 0.779 (0.341–1.480) | 0.553 | 0.794 (0.460–1.370) | 0.407 | 1.246 (0.727–2.134) | 0.423 |
| Other | 0.604 (0.264–1.382) | 0.232 | 0.822 (0.499–1.355) | 0.443 | 1.097 (0.650–1.851) | 0.728 |
| Grade | ||||||
| Well differentiated | 1 | 1 | 1 | |||
| Moderately differentiated | 2.290 (1.416–3.704) | 0.001 | 1.925 (1.206–3.073) | 0.006 | 3.343 (0.816–13.691) | 0.093 |
| Poorly/undifferentiated | 2.771 (1.472–5.214) | 0.002 | 3.848 (2.391–6.192) | <0.001 | 3.565 (0.878–14.471) | 0.075 |
| Tumor stage | ||||||
| T1 | 1 | 1 | 1 | |||
| T2 | 1.437 (0.916–2.185) | 0.089 | 2.307 (1.752–3.039) | <0.001 | 1.843 (1.360–2.497) | 1.843 |
| PR status | ||||||
| Negative | 1 | 1 | 1 | |||
| Positive | 0.672 (0.327–1.380) | 0.279 | 1.354 (0.897–2.043) | 0.149 | 0.879 (0.641–1.205) | 0.422 |
| Chemotherapy | ||||||
| No/unknown | 1 | 1 | 1 | |||
| Yes | 1.575 (0.891–2.783) | 0.118 | 0.832 (0.631–1.095) | 0.189 | 0.733 (0.533–1.010) | 0.058 |
| Surgical procedure | ||||||
| BCS | 1 | 1 | 1 | |||
| MAST | 2.043 (1.422–2.935) | <0.001 | 1.368 (1.051–1.781) | 0.020 | 1.009 (0.740–1.377) | 0.952 |
Abbreviations: MAST, mastectomy; PR, progesterone receptor; T, tumor; BCS, breast-conserving surgery.